Today’s Research Reports on Stocks to Watch: Cara Therapeutics and GW Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 17, 2017 /
Cara Therapeutics and GW Pharmaceuticals are biotech sectors stocks that have been on the rise but now are seeing their stock value changed by both the market and investment ratings firms. Many investors cling to their broker’s recommendations, while others always have one foot out the door. Looking at the stock prices of these companies over the last 30 days and taking into consideration their specific niche specialty may have you wondering the stocks are taking a breather from an upward trend or are headed south for a while.

RDI Initiates
Coverage:

Cara Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CARA

GW Pharmaceuticals
PLC https://ub.rdinvesting.com/news/?ticker=GWPH

Cara Therapeutics is a biopharmaceutical company that develops remedies for pain, with its primary focus on a person’s peripheral nervous system. The stock closed on Thursday at $15.65 a share, up 7 cents. It was not able to recover from the loss of its early morning price of $16.43. It reached its 2017 high price on March 3rd when it closed at $18.04. Recent investment ratings have moved the stock to a “buy” candidate, setting a price objective of between $20 and $22 on the high end. The optimism has funneled over to a few ratings firms that listed it as a “sell” stock. Likewise, some hedge funds have reduced their positions in Cara, while others, including Wells Fargo Bank, MN, have added to their positions. Cara has reported ($0.81) earnings per share (EPS) for the fourth quarter of 2016, missing the Zacks’ consensus estimate of ($0.48) by $0.33.

Access RDI’s Cara Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CARA

Some see GW Pharmaceuticals as one of the more interesting and risky companies on the NASDAQ and in the market in general. The company was created to focused on the development and sale of its therapeutics created from its proprietary cannabinoid product platform. Cannabinoids are found in cannabis, the most potent form being THC, and have a direct effect on the brain’s neurotransmitter cells. The stock closed on Thursday with a price of $122.97, down 98 cents from the previous day close. The stock hit a 90 day high on February 15th, closing at $132.51. But the industry itself is open to regulatory problems from the Federal government and a limited number of sales channels. The company currently only has one drug approved for sale, Sativex. Many investment firms shy away from making recommendations, yet the recommendations that are made tend to be “buy” or “hold” signals with 1 “sell” rating. GW pharmaceutical has reported a loss of GBP 15.6 million on revenue of GBP 2.06 million for the first quarter of fiscal 2017, as compared to reported loss of GBP 17.7 million on revenue of GBP 3.7 million for the same quarter prior year.

Access RDI’s GW Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=GWPH

Our Actionable Research on Cara Therapeutics Inc. (NASDAQ: CARA) and GW Pharmaceuticals PLC (NASDAQ: GWPH) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457538